Publications - 'R'
Publications 1226 - 1250 de 1476
| Titre | DOI |
|---|---|
|
Rituximab and High-Dose Cytarabine Do Not Counteract the Adverse Prognostic Value of CDKN2A and TP53 Deletions in Autografted Mantle-Cell Lymphoma Patients. a European-MCL Network Study M.H. Delfau-Larue; K. Wolfram; F. Berger; F. Jardin; J. Briere; C. Thieblemont; P. Feugier; C. Haioun; G.Andre Salles; V. Ribrag; R.O. Casasnovas; M. Unterhalt; M. Dreyling; C. Pott; E. Macintyre; O. Hermine; E. Hoster 2014 |
|
|
Rituximab and High-Dose Cytarabine Do Not Counteract the Adverse Prognostic Value of CDKN2A and TP53 Deletions in Autografted Mantle-Cell Lymphoma Patients. a European-MCL Network Study M.H. Delfau-Larue; K. Wolfram; F. Berger; F. Jardin; J. Briere; C. Thieblemont; P. Feugier; C. Haioun; G.Andre Salles; V. Ribrag; R.O. Casasnovas; M. Unterhalt; M. Dreyling; C. Pott; E. Macintyre; O. Hermine; E. Hoster 2014 |
|
|
Rituximab exposure is influenced by baseline metabolic tumor volume and predicts outcome of DLBCL patients: a Lymphoma Study Association report M. Tout; O. Casasnovas; M. Meignan; T. Lamy; F. Morschhauser; G. Salles; E. Gyan; C. Haioun; M. Mercier; P. Feugier; S. Boussetta; G. Paintaud; D. Ternant; G. Cartron 2017 |
10.1182/blood-2016-10-744292 |
|
RITUXIMAB FOR RECURRENCE OF PRIMARY FOCAL SEGMENTAL GLOMERULOSCLEROSIS AFTER KIDNEY TRANSPLANTATION: RESULTS OF A NATIONWIDE STUDY C. Lanaret; D. Anglicheau; A. Vincent; C. Lambert; L. Couzi; M. Buchler; S. Ohlmann; D. Bertrand; R. Jean-Philippe; A. Thierry; N. Maillard; B. Schvartz; L. Golbin; V. Pernin; D. Ducloux; N. Bouvier; C. Poulain; A.Elisabeth Heng; C. Greze; P. Malvezzi; F. Martinez; N. Kamar; C. Garrouste 2020 |
|
|
RITUXIMAB FOR RECURRENCE OF PRIMARY FOCAL SEGMENTAL GLOMERULOSCLEROSIS AFTER KIDNEY TRANSPLANTATION: RESULTS OF A NATIONWIDE STUDY C. Lanaret; D. Anglicheau; A. Vincent; C. Lambert; L. Couzi; M. Buchler; S. Ohlmann; D. Bertrand; R. Jean-Philippe; A. Thierry; N. Maillard; B. Schvartz; L. Golbin; V. Pernin; D. Ducloux; N. Bouvier; C. Poulain; A.Elisabeth Heng; C. Greze; P. Malvezzi; F. Martinez; N. Kamar; C. Garrouste 2020 |
|
|
Rituximab for rheumatoid arthritis-associated large granular lymphocytic leukemia, a retrospective case series H. Lobbes; C. Dervout; E. Toussirot; R. Felten; J. Sibilia; D. Wendling; B. Gombert; M. Ruivard; V. Grobost; A. Saraux; D. Cornec; F. Verhoeven; M. Soubrier 2020 |
10.1016/j.semarthrit.2020.05.020 |
|
Rituximab for Severe Membranous Nephropathy: A 6-Month Trial with Extended Follow-Up K. Dahan; H. Debiec; E. Plaisier; M. Cachanado; A. Rousseau; L. Wakselman; P.A. Michel; F. Mihout; B. Dussol; M. Matignon; C. Mousson; T. Simon; P. Ronco; G.E.M.R.I.T.U.X.Study Grp 2017 |
10.1681/ASN.2016040449 |
|
Rituximab Immunomonitoring Predicts Remission in Membranous Nephropathy M. Teisseyre; M. Cremoni; S. Boyer-Suavet; T. Crepin; S. Benzaken; K. Zorzi; V. Esnault; V. Brglez; B. Seitz-Polski 2021 |
10.3389/fimmu.2021.738788 |
|
Rituximab Maintenance after Autologous Stem Cell Transplantation Prolongs Survival in Younger Patients with Mantle Cell Lymphoma: Final Results of the Randomized Phase 3 LyMa Trial of the Lysa/Goelams Group S. Le Gouill; C. Thieblemont; L. Oberic; A. Moreau; K. Bouabdallah; E. Gyan; G. Damaj; V. Ribrag; P. Feugier; O. Casasnovas; H. Zerazhi; C. Haioun; H. Tilly; O. Tournilhac; H. Maisonneuve; P. Solal-Celigny; L.Mathieu Fornecker; E.W. Van den Neste; D. Canioni; G. Salles; T. Lamy; M.C. Bene; R. Gressin; O. Hermine 2016 |
10.1182/blood.V128.22.145.145 |
|
RITUXIMAB MAINTENANCE AFTER AUTOLOGOUS TEM CELL TRANSPLANTATION PROLONGS SURVIVAL IN YOUNGER PATIENTS WITH MANTLE CELL LYMPHOMA: FINAL RESULTS OF THE LYMA TRIAL OF THE LYSA/GOELAMS GROUP S. Le Gouill; C. Thieblemont; L. Oberic; A. Moreau; K. Nouabdallah; E. Gyan; G. Damaj; V. Ribrag; P. Feugier; O. Casasnovas; H. Zerazhi; C. Haioun; H. Tilly; O. Tournilhac; H. Maisonneuve; K. Le Du; L.M. Fornecker; E. Van den Neste; D. Canioni; G. Salles; L. De La Chapelle; M.C. Bene; R. Gressin; O. Hermine 2017 |
|
|
Rituximab Maintenance Versus Wait and Watch after Four Courses of R-DHAP Followed By Autologous Stem Cell transplantation in Previously Untreated Young Patients with Mantle Cell Lymphoma: First Interim Analysis of the Phase III Prospective Lyma Trial, a L S. Le Gouill; C. Thieblemont; L. Oberic; K. Bouabdallah; E. Gyan; G. Damaj; V. Ribrag; S. Bologna; R. Gressin; O. Casasnovas; C. Haioun; P. Solal-Celigny; H. Maisonneuve; E. Van Den Neste; A. Moreau; M.C. Bene; G. Salles; H. Tilly; T. Lamy; O. Hermine 2014 |
10.1182/blood.V124.21.146.146 |
|
RITUXIMAB MAINTENANCE VERSUS WW AFTER R-DHAP PLUS AUTOLOGOUS STEM CELL TRANSPLANTATION IN UNTREATED PATIENTS WITH MCL: INTERIM ANALYSIS OF THE LYMA TRIAL, A LYSA STUDY S. Le Gouill; E. Deconinck; H. Ghesquieres; M. Mertault; B. Audhuy; E. Jourdan; L. Sanhes; R. Bouabdallah; A. Van Hoof; A. Delmer; O. Hermine 2015 |
|
|
RITUXIMAB MAINTENANCE VERSUS WW AFTER R-DHAP PLUS AUTOLOGOUS STEM CELL TRANSPLANTATION IN UNTREATED PATIENTS WITH MCL: INTERIM ANALYSIS OF THE LYMA TRIAL, A LYSA STUDY S. Le Gouill; E. Deconinck; H. Ghesquieres; M. Mertault; B. Audhuy; E. Jourdan; L. Sanhes; R. Bouabdallah; A. Van Hoof; A. Delmer; O. Hermine 2015 |
|
|
Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma F. Morschhauser; N.H. Fowler; P. Feugier; R. Bouabdallah; H. Tilly; M.L. Palomba; C. Fruchart; E.N. Libby; R.O. Casasnovas; I.W. Flinn; C. Haioun; H. Maisonneuve; L. Ysebaert; N.L. Bartlett; K. Bouabdallah; P. Brice; V. Ribrag; N. Daguindau; S. Le Gouill; G.M. Pica; M. Garcia-Sancho; A. Lopez-Guillermo; J.F. Larouche; K. Ando; G. da Silva; M. Andre; P. Zachee; L.H. Sehn; K. Tobinai; G. Cartron; D. Liu; J. Wang; L. Xerri; G.A. Salles; R.E.L.E.V.A.N.C.E.Trial Investigators 2018 |
10.1056/NEJMoa1805104 |
|
RITUXIMAB REVERSED THE INCREASE IN SPLENIC T FOLLICULAR HELPER CELLS DURING IMMUNE THROMBOCYTOPENIA S. Audia; M. Rossato; M. Trad; K. Santegoets; N. Janikashvili; B. Bonnotte; T. Radstake 2014 |
|
|
RITUXIMAB REVERSED THE INCREASE IN SPLENIC T FOLLICULAR HELPER CELLS DURING IMMUNE THROMBOCYTOPENIA S. Audia; M. Rossato; M. Trad; K. Santegoets; N. Janikashvili; B. Bonnotte; T. Radstake 2014 |
|
|
RITUXIMAB REVERSED THE INCREASE IN SPLENIC T FOLLICULAR HELPER CELLS DURING IMMUNE THROMBOCYTOPENIA S. Audia; M. Rossato; M. Trad; K. Santegoets; N. Janikashvili; B. Bonnotte; T. Radstake 2014 |
|
|
Rituximab target-mediated elimination is influenced by both baseline antigenic burden and FCGR3A polymorphism in chronic lymphocytic leukemia M. Tout; A.L. Gagez; S. Lepretre; N. Azzopardi; C. Dartigeas; B. Mahe; E. Ferrand; H. Maisonneuve; T. Aurran; G. Paintaud; G. Cartron; D. Ternant 2016 |
|
|
Rituximab target-mediated elimination is influenced by both baseline antigenic burden and FCGR3A polymorphism in chronic lymphocytic leukemia M. Tout; A.L. Gagez; S. Lepretre; N. Azzopardi; C. Dartigeas; B. Mahe; E. Ferrand; H. Maisonneuve; T. Aurran; G. Paintaud; G. Cartron; D. Ternant 2016 |
|
|
Rituximab Versus Azathioprine for ANCA-Associated Vasculitis Maintenance Therapy: Impact in Health-Related Quality of Life G. Pugnet; C. Pagnoux; A. Karras; C. Khouatra; O. Aumaitre; P. Cohen; F. Maurier; O. Decaux; J. Ninet; P. Gobert; T. Quemeneur; C. Blanchard-Delaunay; P. Godmer; X. Puechal; P.L. Carron; P.Y. Hatron; N. Limal; M. Hamidou; E. Daugas; T. Papo; B. Bonnotte; A. Mahr; B. Terrier; P. Ravaud; L. Mouthon; L. Guillevin 2014 |
|
|
Rituximab Versus Azathioprine for ANCA-Associated Vasculitis Maintenance Therapy: Impact in Health-Related Quality of Life G. Pugnet; C. Pagnoux; A. Karras; C. Khouatra; O. Aumaitre; P. Cohen; F. Maurier; O. Decaux; J. Ninet; P. Gobert; T. Quemeneur; C. Blanchard-Delaunay; P. Godmer; X. Puechal; P.L. Carron; P.Y. Hatron; N. Limal; M. Hamidou; E. Daugas; T. Papo; B. Bonnotte; A. Mahr; B. Terrier; P. Ravaud; L. Mouthon; L. Guillevin 2014 |
|
|
Rituximab versus azathioprine for ANCA-associated vasculitis maintenance therapy: impact on global disability and health-related quality of life G. Pugnet; C. Pagnoux; B. Terrier; E. Perrodeau; X. Puechal; A. Karras; C. Khouatra; O. Aumaitre; P. Cohen; F. Maurier; O. Decaux; J. Ninet; P. Gobert; T. Quemeneur; C. Blanchard-Delaunay; P. Godmer; P.L. Carron; P.Y. Hatron; N. Limal; M. Hamidou; M. Ducret; E. Daugas; T. Papo; B. Bonnotte; A. Mahr; P. Ravaud; L. Mouthon; L. Guillevin; F.Vasculitis Grp 2016 |
|
|
Rituximab versus azathioprine for ANCA-associated vasculitis maintenance therapy: impact on global disability and health-related quality of life G. Pugnet; C. Pagnoux; B. Terrier; E. Perrodeau; X. Puechal; A. Karras; C. Khouatra; O. Aumaitre; P. Cohen; F. Maurier; O. Decaux; J. Ninet; P. Gobert; T. Quemeneur; C. Blanchard-Delaunay; P. Godmer; P.L. Carron; P.Y. Hatron; N. Limal; M. Hamidou; M. Ducret; E. Daugas; T. Papo; B. Bonnotte; A. Mahr; P. Ravaud; L. Mouthon; L. Guillevin; F.Vasculitis Grp 2016 |
|
|
Rituximab versus Azathioprine for Maintenance in ANCA-Associated Vasculitis L. Guillevin; C. Pagnoux; A. Karras; C. Khouatra; O. Aumaitre; P. Cohen; F. Maurier; O. Decaux; J. Ninet; P. Gobert; T. Quemeneur; C. Blanchard-Delaunay; P. Godmer; X. Puechal; P.L. Carron; P.Y. Hatron; N. Limal; M. Hamidou; M. Ducret; E. Daugas; T. Papo; B. Bonnotte; A. Mahr; P. Ravaud; L. Mouthon; F.Vasculitis Grp 2014 |
10.1056/NEJMoa1404231 |
|
Rituximab-resistant splenic memory B cells and newly engaged naive B cells fuel relapses in patients with immune thrombocytopenia E. Crickx; P. Chappert; A. Sokal; S. Weller; I. Azzaoui; A. Vandenberghe; G. Bonnard; G. Rossi; T. Fadeev; S. Storck; J. Fadlallah; V. Meignin; E. Riviere; S. Audia; B. Godeau; M. Michel; J.C. Weill; C.A. Reynaud; M. Mahevas 2021 |
10.1126/scitranslmed.abc3961 |